1 July 2025
\n \n \n \nThe BioEscalator is very proud to be home to a stellar collection of companies using cutting-edge science to tackle profound medical challenges. Our new Portfolio 2025 brings them together to showcase their innovative approaches and provide a valuable guide for potential investors and partners.
\n \n\n \n \n29 June 2025
\n \n \n \nOxford-based Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed Dr Quin Wills as CEO.
\n \n\n \n \n4 June 2025
\n \n \n \nStay updated with the latest BioEscalator updates, tenant and alumni news, and upcoming events in the Summer 2025 edition of the BioEscalator Bulletin.
\n \n\n \n \n28 May 2025
\n \n \n \nThe appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics.
\n \n\n \n \n27 May 2025
\n \n \n \nPGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs. PGN-EDO51 at 10 mg/kg was generally well tolerated; all treatment-related adverse events were mild. DM1 program on track to read out FREEDOM-DM1 15 mg/kg cohort in second half of 2025 and FREEDOM2-DM1 5 mg/kg cohort in Q1 2026.
\n \n\n \n \n26 May 2025
\n \n \n \nNucleome Therapeutics (\u2018Nucleome\u2019 or \u2018the Company\u2019), a biotechnology\r\ncompany harnessing the power of non-coding human genetics to discover first-in-class antibody\r\ntreatments for inflammatory diseases, announces it has appointed Bhavna Hunjan as Chief Business\r\nOfficer with immediate effect.
\n \n\n \n \n22 May 2025
\n \n \n \nWe are excited to announce that Sandbox Bioscience, an ambitious biotech start-up founded by a team of virology experts from the Oxford ecosystem, has joined the BioEscalator.
\n \n\n \n \n19 May 2025
\n \n \n \nPepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies.
\n \n\n \n \n5 May 2025
\n \n \n \nAlchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab\u2019s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.
\n \n\n \n \n1 May 2025
\n \n \n \nU\u2011Ploid, a biotechnology company developing first-in-class therapeutics to address age-related infertility, today announced its selection for the inaugural Merck Corporate Accelerator. The programme, launched by EMD Serono in partnership with the Society for Innovation and Startups (SIS), is designed to support breakthrough innovation in women\u2019s health by providing funding, expert mentorship, and access to Merck\u2019s global network of scientific and clinical leaders.
\n \n\n \n \n30 April 2025
\n \n \n \nEnara Bio, a biopharmaceutical company pioneering the development of bispecific T-cell engagers directed against Dark Antigen\u00ae and other emerging targets, today announces the appointment of Stacey Davis as Chief Business Officer (CBO) and Chief Financial Officer (CFO). Her appointment strengthens the leadership team at a key moment for Enara as it prepares to transition its lead assets towards clinical development. Stacey most recently served as CBO at Xilio Therapeutics, where she was the architect of a series of major pharma collaborations. In total, Stacey brings over 25 years of experience in delivering growth, innovation, and strategic transformation in the biotech and pharmaceutical industries.
\n \n\n \n \n9 April 2025
\n \n \n \nOrfonyx Bio is looking to make its mark as a leader in protein upregulation for clinical benefit \u2013 and has made technical progress towards this goal over the past two years. In that time as a BioEscalator tenant the University of Oxford spin-out has also grown from two to seven employees, raised an Oxford Science Enterprises-backed seed round and started to understand where its approach might have the greatest clinical impact. Now it\u2019s raising additional funding.
\n \n\n \n \n8 April 2025
\n \n \n \nInfinitopes Ltd today announces that the UK Medicines and Healthcare products RegulatoryAgency (MHRA) has granted Clinical Trial Application (CTA) approval for the first-in-humanPhase I/IIa clinical trial of ITOP1, the company\u2019s lead \u2018off-the-shelf\u2019 cancer vaccine. ITOP1 is a precision cancer vaccine, designed to safely and accurately target tumour antigens, leveraging the company\u2019s vector delivery system, aiming to drive strong and durable T-cell protection for patients with surgically resectable oesophageal adenocarcinoma (OAC).
\n \n\n \n \n7 April 2025
\n \n \n \nCare Fertility, a leading fertility treatment provider, and U-Ploid Biotechnologies, a pioneering reproductive health biotech, today announces a research collaboration aimed at improving egg quality and improve fertility treatment. Egg quality is one of the main contributing factors to infertility and is known to deteriorate rapidly with increasing female age. This research collaboration has the potential to validate novel therapeutics and offer hope to millions struggling to conceive.
\n \n\n \n \n5 April 2025
\n \n \n \nDr Vinson brings over 25 years of invaluable experience in the pharma and biotech industry, with a proven track record of leading and contributing to breakthrough therapeutics.
\n \n\n \n \n30 March 2025
\n \n \n \nPepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company.
\n \n\n \n \n26 March 2025
\n \n \n \nMoa recognised as leading global innovator in environmental impact.
\n \n\n \n \n25 March 2025
\n \n \n \nMoa and NAICONS join forces to discover the next generation of naturally-occurring herbicides.
\n \n\n \n \n20 March 2025
\n \n \n \nInfinitopes welcomes Jo Brewer, PhD (CSO at Adaptimmune), and Dan Menichella (former CEO and CBO of CureVac's US subsidiary) as incoming Non-Executive Directors, bringing deep expertise in immunotherpay and oncology innovation.
\n \n\n \n \n20 March 2025
\n \n \n \nTo celebrate International Women's Day 2025, the BioEscalator was delighted to host a double panel discussion and networking event with EnSpire Oxford and Advanced Oxford.
\n \n\n \n \n